Dr James Roberts is a cellular and molecular biologist with a background in cardiovascular toxicity induced by chemotherapeutics and associated protection by antioxidants. He completed his PhD exploring NRF2 molecular mechanisms contributing to the mitigation of doxorubicin-induced cardio-toxicity at the University of Liverpool in 2024. Since achieving a post-doctoral position at the University of Birmingham, Dr Roberts has worked in the neuro-ophthalmology group lead by Associate Professor Lisa Hill and Dr Hannah Botfield. His research focusses on improving drug delivery for sight-threatening ocular diseases including age-related macular degeneration and glaucoma. Furthermore, this research is seeking to explore novel therapeutics for the treatment of ocular and neurodegenerative diseases more widely.
Dr Roberts is also a key member of the biofluids workstream within the pioneering mTBI-PREDICT clinical study, a long-term multicentre study aiming to identify clinical biomarkers to identify risks in those who have suffered mild traumatic brain injury (mTBI).